Icosavax, Inc.
NASDAQ:ICVX
15.31 (USD) • At close February 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Icosavax, Inc. |
Symbool | ICVX |
Munteenheid | USD |
Prijs | 15.31 |
Beurswaarde | 769,036,610 |
Dividendpercentage | 0% |
52-weken bereik | 4.75 - 16.105 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adam K. Simpson |
Website | https://icosavax.com |
An error occurred while fetching data.
Over Icosavax, Inc.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)